

Bapineuzumab for mild to moderate Alzheimer's disease trials

Alzheimer's Research and Therapy

8, 18

DOI: [10.1186/s13195-016-0189-7](https://doi.org/10.1186/s13195-016-0189-7)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Antibody-Based Drugs and Approaches Against Amyloid- $\beta^2$ Species for Alzheimer's Disease Immunotherapy. <i>Drugs and Aging</i> , 2016, 33, 685-697.	1.3	48
2	Tau passive immunization inhibits not only tau but also A $\beta^2$ pathology. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 1.	3.0	147
3	Do anti-amyloid beta protein antibody cross reactivities confound Alzheimer disease research?. <i>Journal of Negative Results in BioMedicine</i> , 2017, 16, 1.	1.4	51
4	Immune Regulation of Antibody Access to Neuronal Tissues. <i>Trends in Molecular Medicine</i> , 2017, 23, 227-245.	3.5	48
5	EFAD transgenic mice as a human APOE relevant preclinical model of Alzheimer's disease. <i>Journal of Lipid Research</i> , 2017, 58, 1733-1755.	2.0	56
6	Why do trials for Alzheimer's disease drugs keep failing? A discontinued drug perspective for 2010-2015. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 735-739.	1.9	469
7	Cerebrospinal Fluid Amyloid- $\beta^2$ 42, Total Tau and Phosphorylated Tau are Low in Patients with Normal Pressure Hydrocephalus: Analogies and Differences with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 183-200.	1.2	31
8	Advanced Drug Discovery for Alzheimer's Disease: Challenges and Strategies. , 2017, , 9-29.		0
9	Lessons from Anti-Amyloid- $\beta^2$ Immunotherapies in Alzheimer Disease: Aiming at a Moving Target. <i>Neurodegenerative Diseases</i> , 2017, 17, 242-250.	0.8	34
10	Inhibiting the Ca <sup>2+</sup> Influx Induced by Human CSF. <i>Cell Reports</i> , 2017, 21, 3310-3316.	2.9	20
11	Why do so many clinical trials of therapies for Alzheimer's disease fail?. <i>Lancet</i> , The, 2017, 390, 2327-2329.	6.3	193
12	Role of Vitamin D in Amyloid clearance via LRP-1 upregulation in Alzheimer's disease: A potential therapeutic target?. <i>Journal of Chemical Neuroanatomy</i> , 2017, 85, 36-42.	1.0	32
13	A vaccine with A $\beta^2$ oligomer-specific mimotope attenuates cognitive deficits and brain pathologies in transgenic mice with Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 41.	3.0	9
14	Longitudinal Neuroimaging Analysis in Mild-Moderate Alzheimer's Disease Patients Treated with Plasma Exchange with 5% Human Albumin. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 321-332.	1.2	21
15	Increased expression of Myc-interacting zinc finger protein 1 in APP/PS1 mice. <i>Experimental and Therapeutic Medicine</i> , 2017, 14, 5751-5756.	0.8	3
16	Old Maids: Aging and Its Impact on Microglia Function. <i>International Journal of Molecular Sciences</i> , 2017, 18, 769.	1.8	163
17	Long-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2017, 14, 696-708.	0.7	43
18	A novel monoclonal antibody against the N-terminus of A $\beta^2$ 1-42 reduces plaques and improves cognition in a mouse model of Alzheimer's disease. <i>PLoS ONE</i> , 2017, 12, e0180076.	1.1	13

#	ARTICLE	IF	CITATIONS
19	Drug candidates in clinical trials for Alzheimer's disease. <i>Journal of Biomedical Science</i> , 2017, 24, 47.	2.6	330
20	A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 95.	3.0	396
21	The role of PI3K/AKT pathway and its therapeutic possibility in Alzheimer's disease. <i>Hanyang Medical Reviews</i> , 2017, 37, 18.	0.4	20
22	Dale Schenk One Year Anniversary: Fighting to Preserve the Memories. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1-13.	1.2	7
23	Transthyretin Mimetics as Anti-A $\beta$ Amyloid Agents: A Comparison of Peptide and Protein Approaches. <i>ChemMedChem</i> , 2018, 13, 968-979.	1.6	23
24	Prospects for strain-specific immunotherapy in Alzheimer's disease and tauopathies. <i>Npj Vaccines</i> , 2018, 3, 9.	2.9	45
25	Increase in brain atrophy after subdural hematoma to rates greater than associated with dementia. <i>Journal of Neurosurgery</i> , 2018, 129, 1579-1587.	0.9	15
26	Phos-tau peptide immunization of amyloid-tg-mice reduced non-mutant phos-tau pathology, improved cognition and reduced amyloid plaques. <i>Experimental Neurology</i> , 2018, 303, 48-58.	2.0	9
27	Anti-A $\beta$ drug candidates in clinical trials and plasmonic nanoparticle-based drug-screen for Alzheimer's disease. <i>Analyst</i> , 2018, 143, 2204-2212.	1.7	19
28	DETECTING TREATMENT GROUP DIFFERENCES IN ALZHEIMER'S DISEASE CLINICAL TRIALS: A COMPARISON OF ALZHEIMER'S DISEASE ASSESSMENT SCALE - COGNITIVE SUBSCALE (ADAS-COG) AND THE CLINICAL DEMENTIA RATING - SUM OF BOXES (CDR-SB). <i>Journal of Prevention of Alzheimer's Disease</i> , 2018, 5, 1-6.		8
30	Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1409-1424.	1.2	22
31	Dihydroquinoline Carbamate DQS1-02 as a Prodrug of a Potent Acetylcholinesterase Inhibitor for Alzheimer's Disease Therapy: Multigram-Scale Synthesis, Mechanism Investigations, In Vitro Safety Pharmacology, and Preliminary In Vivo Toxicology Profile. <i>ACS Omega</i> , 2018, 3, 18387-18397.	1.6	7
32	The influence of language and culture on cognitive assessment tools in the diagnosis of early cognitive impairment and dementia. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 859-869.	1.4	29
33	Neurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic Approaches. <i>Brain Sciences</i> , 2018, 8, 177.	1.1	139
34	A $\beta$ and the dementia syndrome: Simple versus complex perspectives. <i>European Journal of Clinical Investigation</i> , 2018, 48, e13025.	1.7	11
35	Representation of ethnic groups in dementia trials: systematic review and meta-analysis. <i>Journal of the Neurological Sciences</i> , 2018, 394, 107-111.	0.3	20
36	Passive A $\beta$ Immunotherapy: Current Achievements and Future Perspectives. <i>Molecules</i> , 2018, 23, 1068.	1.7	41
37	The Place of PET to Assess New Therapeutic Effectiveness in Neurodegenerative Diseases. <i>Contrast Media and Molecular Imaging</i> , 2018, 2018, 1-15.	0.4	15

#	ARTICLE	IF	CITATIONS
38	Alzheimer's Disease Model System Using Drosophila. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1076, 25-40.	0.8	33
39	Early A $\beta$ -Hbc virus-like particles immunization had better effects on preventing the deficit of learning and memory abilities and reducing cerebral A $\beta$ load in PDAPP mice. <i>Vaccine</i> , 2018, 36, 5258-5264.	1.7	1
40	Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 54.	3.0	24
41	Antibody Engineering for Optimized Immunotherapy in Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2018, 12, 254.	1.4	17
42	Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer's Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 689-707.	1.2	15
43	Multicrossover Randomized Controlled Trial Designs in Alzheimer Disease. <i>Annals of Neurology</i> , 2018, 84, 168-175.	2.8	11
44	An in vitro paradigm to assess potential anti-A $\beta$ antibodies for Alzheimer's disease. <i>Nature Communications</i> , 2018, 9, 2676.	5.8	50
45	Psychosocial interventions for Alzheimer's disease cognitive symptoms: a Bayesian network meta-analysis. <i>BMC Geriatrics</i> , 2018, 18, 175.	1.1	67
46	Tau-targeting therapies for Alzheimer disease. <i>Nature Reviews Neurology</i> , 2018, 14, 399-415.	4.9	748
47	Triggering receptor expressed on myeloid cells 2 (TREM2): a potential therapeutic target for Alzheimer disease?. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 587-598.	1.5	27
48	A Novel Method to Estimate Long-Term Chronological Changes From Fragmented Observations in Disease Progression. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 436-447.	2.3	12
49	Drug development for Alzheimer's disease: review. <i>Journal of Drug Targeting</i> , 2019, 27, 164-173.	2.1	60
50	Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 328-337.	1.8	25
51	Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer's disease tau. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 67.	3.0	28
52	Structure and Function of Alzheimer's Amyloid $\beta$ Proteins from Monomer to Fibrils: A Mini Review. <i>Protein Journal</i> , 2019, 38, 425-434.	0.7	21
53	A Rationally Designed Humanized Antibody Selective for Amyloid Beta Oligomers in Alzheimer's Disease. <i>Scientific Reports</i> , 2019, 9, 9870.	1.6	35
54	Linking Late Life Depression and Alzheimer's Disease: Mechanisms and Resilience. <i>Current Behavioral Neuroscience Reports</i> , 2019, 6, 103-112.	0.6	18
55	Hospital psychosocial interventions for patients with brain functional impairment: A retrospective cohort study. <i>International Journal of Mental Health Nursing</i> , 2019, 28, 1155-1164.	2.1	0

#	ARTICLE	IF	CITATIONS
56	Developing Effective Alzheimer's Disease Therapies: Clinical Experience and Future Directions. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 715-732.	1.2	89
57	Development of new treatments for Alzheimer's disease based on the modulation of translocator protein (TSPO). <i>Ageing Research Reviews</i> , 2019, 54, 100943.	5.0	10
58	The P2X7 receptor: a new therapeutic target in Alzheimer's disease. <i>Expert Opinion on Therapeutic Targets</i> , 2019, 23, 165-176.	1.5	37
59	Longitudinal multimodal imaging and clinical endpoints for frontotemporal dementia clinical trials. <i>Brain</i> , 2019, 142, 443-459.	3.7	65
60	Unifying Hypothesis of Dopamine Neuron Loss in Neurodegenerative Diseases: Focusing on Alzheimer's Disease. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 123.	1.4	49
62	Impact of Pre-Analytical Differences on Biomarkers in the ADNI and PPMI Studies: Implications in the Era of Classifying Disease Based on Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 263-276.	1.2	13
63	The potential of memory enhancement through modulation of perineuronal nets. <i>British Journal of Pharmacology</i> , 2019, 176, 3611-3621.	2.7	27
64	Pharmacists a valuable resource for patients with Alzheimer disease and their caregivers. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2019, 59, 770-772.	0.7	0
65	Reasons for Failed Trials of Disease-Modifying Treatments for Alzheimer Disease and Their Contribution in Recent Research. <i>Biomedicines</i> , 2019, 7, 97.	1.4	161
66	Friend, Foe or Both? Immune Activity in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 337.	1.7	63
67	IgG Fc N-glycosylation: Alterations in neurologic diseases and potential therapeutic target?. <i>Journal of Autoimmunity</i> , 2019, 96, 14-23.	3.0	31
68	The Mode of Action of an Anti-Oligomeric Amyloid $\beta$ -Protein Antibody Affects its Protective Efficacy. <i>Neurotoxicity Research</i> , 2019, 35, 304-317.	1.3	7
69	The application of positron emission tomography (PET) imaging in CNS drug development. <i>Brain Imaging and Behavior</i> , 2019, 13, 354-365.	1.1	32
70	The unfolded protein response in neurodegenerative disorders – therapeutic modulation of the PERK pathway. <i>FEBS Journal</i> , 2019, 286, 342-355.	2.2	137
71	Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH EXAMINER as a potential clinical trial endpoint. <i>Alzheimer's and Dementia</i> , 2020, 16, 11-21.	0.4	32
72	Improvements of symptoms of Alzheimer's disease by inhibition of the angiotensin system. <i>Pharmacological Research</i> , 2020, 154, 104230.	3.1	37
73	BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease. <i>Medicinal Research Reviews</i> , 2020, 40, 339-384.	5.0	177
74	Endosomal dysfunction impacts extracellular vesicle release: Central role in $A\beta$ pathology. <i>Ageing Research Reviews</i> , 2020, 58, 101006.	5.0	29

#	ARTICLE	IF	CITATIONS
75	The Brain-Heart Axis: Alzheimer's, Diabetes, and Hypertension. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 21-28.	2.5	19
76	Smart treatment strategies for alleviating tauopathy and neuroinflammation to improve clinical outcome in Alzheimer's disease. <i>Drug Discovery Today</i> , 2020, 25, 2110-2129.	3.2	12
77	Alzheimer's disease: Recent treatment strategies. <i>European Journal of Pharmacology</i> , 2020, 887, 173554.	1.7	300
78	An Immunomodulatory Therapeutic Vaccine Targeting Oligomeric Amyloid- $\beta$ . <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1639-1653.	1.2	8
79	Blood-brain barrier integrity in the pathogenesis of Alzheimer's disease. <i>Frontiers in Neuroendocrinology</i> , 2020, 59, 100857.	2.5	50
80	The Functional Roles and Applications of Immunoglobulins in Neurodegenerative Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5295.	1.8	18
81	Escitalopram Alleviates Alzheimer's Disease-Type Tau Pathologies in the Aged P301L Tau Transgenic Mice. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 807-819.	1.2	10
82	Pyk2 overexpression in postsynaptic neurons blocks amyloid $\beta$ -42-induced synaptotoxicity in microfluidic co-cultures. <i>Brain Communications</i> , 2020, 2, fcaa139.	1.5	13
83	Modulation of Brain Hyperexcitability: Potential New Therapeutic Approaches in Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9318.	1.8	54
84	Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer's Disease Dementia: Findings from the Ontario Neurodegenerative Disease Research Initiative (ONDRI) Study and Clinical Trials Over the Past 10 Years. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 747-757.	1.2	9
85	N-terminal heterogeneity of parenchymal and vascular amyloid $\beta$ deposits in Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2020, 46, 673-685.	1.8	20
86	Alzheimer's: Are we winning the fight? Not so sure. <i>Revue Neurologique</i> , 2020, 176, 299-300.	0.6	2
87	Disclosing genetic risk for Alzheimer's dementia to individuals with mild cognitive impairment. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12002.	1.8	16
88	Molecular Pathogenesis and Interventional Strategies for Alzheimer's Disease: Promises and Pitfalls. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 472-488.	2.5	21
89	The role of the immune system in driving neuroinflammation. <i>Brain and Neuroscience Advances</i> , 2020, 4, 239821281990108.	1.8	42
90	Current and Future Treatments in Alzheimer Disease: An Update. <i>Journal of Central Nervous System Disease</i> , 2020, 12, 117957352090739.	0.7	413
91	High blood pressure predicts hippocampal atrophy rate in cognitively impaired elders. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12035.	1.2	6
92	Counteracting role of nuclear factor erythroid 2-related factor 2 pathway in Alzheimer's disease. <i>Biomedicine and Pharmacotherapy</i> , 2020, 129, 110373.	2.5	56

#	ARTICLE	IF	CITATIONS
93	Protofibrils of Amyloid- $\beta^2$ are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 952.	1.8	41
94	Novel small molecule therapeutic agents for Alzheimer disease: Focusing on BACE1 and multi-target directed ligands. <i>Bioorganic Chemistry</i> , 2020, 97, 103649.	2.0	61
95	Development of the clinical candidate PBD-CO6, a humanized pGlu3-A $\beta^2$ -specific antibody against Alzheimer's disease with reduced complement activation. <i>Scientific Reports</i> , 2020, 10, 3294.	1.6	17
96	Auditory evoked potentials might have the potential to serve as early indicators related to amyloid beta peptide toxicity. <i>Advances in Medical Sciences</i> , 2020, 65, 223-232.	0.9	4
97	Sex and gender differences in Alzheimer's disease: current challenges and implications for clinical practice. <i>European Journal of Neurology</i> , 2020, 27, 928-943.	1.7	81
98	Computer-Aided Drug Design of $\beta^2$ -Secretase, $\beta^3$ -Secretase and Anti-Tau Inhibitors for the Discovery of Novel Alzheimer's Therapeutics. <i>International Journal of Molecular Sciences</i> , 2020, 21, 703.	1.8	45
99	Resveratrol Derivatives as Potential Treatments for Alzheimer's and Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 103.	1.7	79
100	Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study. <i>Alzheimer's and Dementia</i> , 2020, 16, 750-758.	0.4	29
101	Flavonoids as an Intervention for Alzheimer's Disease: Progress and Hurdles Towards Defining a Mechanism of Action. <i>Brain Plasticity</i> , 2021, 6, 167-192.	1.9	36
102	Partial Inhibition of Mitochondrial Complex I Reduces Tau Pathology and Improves Energy Homeostasis and Synaptic Function in 3xTg-AD Mice. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 335-353.	1.2	22
103	Whether cognitive behavioral therapy is effective for Alzheimer's disease. <i>Medicine (United States)</i> , 2021, 100, e23945.	0.4	2
104	Monoclonal Antibodies as Neurological Therapeutics. <i>Pharmaceuticals</i> , 2021, 14, 92.	1.7	35
105	Microvascular Alterations in Alzheimer's Disease. <i>Frontiers in Cellular Neuroscience</i> , 2020, 14, 618986.	1.8	41
106	Flavonoid-Based Nanomedicines in Alzheimer's Disease Therapeutics: Promises Made, a Long Way To Go. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 74-95.	2.5	16
107	Role of Adaptive Immune and Impacts of Risk Factors on Adaptive Immune in Alzheimer's Disease: Are Immunotherapies Effective or Off-Target?. <i>Neuroscientist</i> , 2022, 28, 254-270.	2.6	9
109	Quantification of N-terminal amyloid- $\beta^2$ isoforms reveals isomers are the most abundant form of the amyloid- $\beta^2$ peptide in sporadic Alzheimer's disease. <i>Brain Communications</i> , 2021, 3, fcab028.	1.5	25
110	Are extracellular vesicles new hope in clinical drug delivery for neurological disorders?. <i>Neurochemistry International</i> , 2021, 144, 104955.	1.9	17
111	Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2805.	1.8	8

#	ARTICLE	IF	CITATIONS
112	Strategies to reduce sample sizes in Alzheimer's disease primary and secondary prevention trials using longitudinal amyloid PET imaging. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 82.	3.0	14
113	Modulating innate immune activation states impacts the efficacy of specific A $\beta$ immunotherapy. <i>Molecular Neurodegeneration</i> , 2021, 16, 32.	4.4	4
114	Tau-Targeted Multifunctional Nanoinhibitor for Alzheimer's Disease. <i>ACS Applied Materials &amp; Interfaces</i> , 2021, 13, 23328-23338.	4.0	24
115	Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity. <i>Neurology</i> , 2021, 96, e2673-e2684.	1.5	37
116	PET Agents in Dementia: An Overview. <i>Seminars in Nuclear Medicine</i> , 2021, 51, 196-229.	2.5	23
117	Cognitive Go/No-Go decision-making criteria in Alzheimer's disease drug development. <i>Drug Discovery Today</i> , 2021, 26, 1330-1336.	3.2	3
118	Emerging insights into the role of albumin with plasma exchange in Alzheimer's disease management. <i>Transfusion and Apheresis Science</i> , 2021, 60, 103164.	0.5	12
119	Factors affecting the efficacy of repetitive transcranial magnetic stimulation for patients with Alzheimer's disease. <i>Zhejiang Da Xue Xue Bao Yi Xue Ban = Journal of Zhejiang University Medical Sciences</i> , 2021, 50, 383-389.	0.1	2
120	The Progress of Label-Free Optical Imaging in Alzheimer's Disease Screening and Diagnosis. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 699024.	1.7	4
121	Effects of monoclonal antibodies against amyloid- $\beta$ on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease. <i>Ageing Research Reviews</i> , 2021, 68, 101339.	5.0	118
122	Novel Biomarkers of Alzheimer's Disease: Based Upon N-methyl-D-aspartate Receptor Hypoactivation and Oxidative Stress. <i>Clinical Psychopharmacology and Neuroscience</i> , 2021, 19, 423-433.	0.9	11
123	Identification of ortho catechol-containing isoflavone as a privileged scaffold that directly prevents the aggregation of both amyloid $\beta$ plaques and tau-mediated neurofibrillary tangles and its in vivo evaluation. <i>Bioorganic Chemistry</i> , 2021, 113, 105022.	2.0	7
124	Incident stroke in patients with Alzheimer's disease: systematic review and meta-analysis. <i>Scientific Reports</i> , 2021, 11, 16385.	1.6	11
125	The Development of Pharmacological Therapies for Alzheimer's Disease. <i>Neurology and Therapy</i> , 2021, 10, 609-626.	1.4	10
126	Immune modulations and immunotherapies for Alzheimer's disease: a comprehensive review. <i>Reviews in the Neurosciences</i> , 2022, 33, 365-381.	1.4	5
127	Proportion of Women and Reporting of Outcomes by Sex in Clinical Trials for Alzheimer Disease. <i>JAMA Network Open</i> , 2021, 4, e2124124.	2.8	30
128	Amyloid- $\beta$ and $\beta$ -Synuclein Immunotherapy: From Experimental Studies to Clinical Trials. <i>Frontiers in Neuroscience</i> , 2021, 15, 733857.	1.4	25
129	The Ups and Downs of Amyloid in Alzheimer's. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 2022, 9, 1-4.	1.5	2



#	ARTICLE	IF	CITATIONS
130	Advances in Drug Therapy for Alzheimer's Disease. <i>Current Medical Science</i> , 2020, 40, 999-1008.	0.7	18
131	OUP accepted manuscript. <i>Brain</i> , 2021, 144, 434-449.	3.7	54
132	Transcranial optical imaging reveals a pathway for optimizing the delivery of immunotherapeutics to the brain. <i>JCI Insight</i> , 2018, 3, .	2.3	64
133	The neuroprotective effects of SIRT1 in mice carrying the APP/PS1 double-transgenic mutation and in SH-SY5Y cells over-expressing human APP670/671 may involve elevated levels of $\pm 7$ nicotinic acetylcholine receptors. <i>Aging</i> , 2020, 12, 1792-1807.	1.4	15
134	Therapeutic Strategies Targeting Amyloid- $\beta^2$ in Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2019, 16, 418-452.	0.7	88
135	Current Status of Drug Targets and Emerging Therapeutic Strategies in the Management of Alzheimer's Disease. <i>Current Neuropharmacology</i> , 2020, 18, 883-903.	1.4	17
136	Past, present and future of therapeutic strategies against amyloid- $\beta^2$ peptides in Alzheimer's disease: a systematic review. <i>Ageing Research Reviews</i> , 2021, 72, 101496.	5.0	131
137	Re: Glemsk og glemt. <i>Tidsskrift for Den Norske Laegeforening</i> , 2017, 137, 685-685.	0.2	0
141	RhoA/Rock2/Limk1/cofilin1 pathway is involved in attenuation of neuronal dendritic spine loss by paeonol in the frontal cortex of D-galactose and aluminum-induced Alzheimer's disease-like rat model. <i>Acta Neurobiologiae Experimentalis</i> , 2020, 80, 225-244.	0.4	13
142	Pharmacogenomic approaches to the treatment of sporadic Alzheimer's disease. , 2020, , 81-94.		0
143	The Emerging Role of Metabolism in Brain-Heart Axis: New Challenge for the Therapy and Prevention of Alzheimer Disease. May Thioredoxin Interacting Protein (TXNIP) Play a Role?. <i>Biomolecules</i> , 2021, 11, 1652.	1.8	6
145	Immunopharmacology of Alzheimer's disease. , 2022, , 277-298.		0
146	Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 2022, 9, 211-220.	1.5	25
147	Can the entorhinal cortex help distinguish healthy aging brains from pathological aging brains?. <i>Aging Brain</i> , 2022, 2, 100026.	0.7	0
148	Amyloid-Related Imaging Abnormalities and $\beta^2$ -Amyloid-Targeting Antibodies. <i>JAMA Neurology</i> , 2022, 79, 291.	4.5	43
149	New Perspectives for Treatment in Alzheimer's Disease. , 2022, , 199-225.		0
150	Safety and Efficacy of Monoclonal Antibodies for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Published and Unpublished Clinical Trials. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 101-129.	1.2	31
151	Alzheimer's Disease: Key Insights from Two Decades of Clinical Trial Failures. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 83-100.	1.2	56

#	ARTICLE	IF	CITATIONS
152	Role of Pharmacogenomics in Individualizing Treatment for Alzheimer's Disease. <i>CNS Drugs</i> , 2022, 36, 365-376.	2.7	6
153	Association of CSF A $\beta$ Levels With Risk of Alzheimer Disease-Related Decline. <i>Neurology</i> , 2022, 98, .	1.5	16
154	Impact of Anti-amyloid- $\beta$ Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer's Disease: A Focus on Aducanumab and Lecanemab. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 870517.	1.7	91
157	Therapeutic news in Alzheimer's disease: Soon a disease-modifying therapy?. <i>Revue Neurologique</i> , 2022, 178, 437-440.	0.6	8
158	NMDA Inhibitors: A Potential Contrivance to Assist in Management of Alzheimer Disease. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2022, 25, .	0.6	1
159	A comparison of advanced semi-quantitative amyloid PET analysis methods. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 4097-4108.	3.3	4
160	Physiological Roles of Monomeric Amyloid- $\beta$ and Implications for Alzheimer's Disease Therapeutics. <i>Experimental Neurobiology</i> , 2022, 31, 65-88.	0.7	21
161	Magnetic resonance imaging measures of brain volumes across the EXPEDITION trials in mild and moderate Alzheimer's disease dementia. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2022, 8, .	1.8	0
162	Neuroimaging analyses from a randomized, controlled study to evaluate plasma exchange with albumin replacement in mild-to-moderate Alzheimer's disease: additional results from the AMBAR study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 4589-4600.	3.3	4
163	Adenosine receptor signalling in Alzheimer's disease. <i>Purinergic Signalling</i> , 2022, 18, 359-381.	1.1	5
164	Incidence of Amyloid-Related Imaging Abnormalities in Patients With Alzheimer Disease Treated With Anti- $\beta$ -Amyloid Immunotherapy. <i>Neurology</i> , 2022, 99, .	1.5	13
165	Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2023, 19, 708-720.	0.4	16
166	Feasibility, safety, and tolerability of two modalities of plasma exchange with albumin replacement to treat elderly patients with Alzheimer's disease in the AMBAR study. <i>Journal of Clinical Apheresis</i> , 2023, 38, 45-54.	0.7	2
167	Vascular Considerations for Amyloid Immunotherapy. <i>Current Neurology and Neuroscience Reports</i> , 2022, 22, 709-719.	2.0	3
168	Subcortical signal alteration of corticospinal tracts. A radiologic manifestation of ARIA: A case report. <i>Radiology Case Reports</i> , 2023, 18, 275-279.	0.2	3
169	Science disconnected: the translational gap between basic science, clinical trials, and patient care in Alzheimer's disease. <i>The Lancet Healthy Longevity</i> , 2022, 3, e797-e803.	2.0	6
170	Postulating the possible cellular signalling mechanisms of antibody drug conjugates in Alzheimer's disease. <i>Cellular Signalling</i> , 2023, 102, 110539.	1.7	5
171	Upregulation of Ca <sup>2+</sup> -binding proteins contributes to VTA dopamine neuron survival in the early phases of Alzheimer's disease in Tg2576 mice. <i>Molecular Neurodegeneration</i> , 2022, 17, .	4.4	16

#	ARTICLE	IF	CITATIONS
172	A review of therapeutic failures in late-stage clinical trials. <i>Expert Opinion on Pharmacotherapy</i> , 2023, 24, 389-399.	0.9	1
173	Multimodality imaging of neurodegenerative disorders with a focus on multiparametric magnetic resonance and molecular imaging. <i>Insights Into Imaging</i> , 2023, 14, .	1.6	5
174	Neuronal deletion of nSMase2 reduces the production of A $\beta$ and directly protects neurons. <i>Neurobiology of Disease</i> , 2023, 177, 105987.	2.1	0
175	Advances in Alzheimer's disease's pharmacological treatment. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	10
176	Peripheral administration of nanomicelle-encapsulated anti-A $\beta$ oligomer fragment antibody reduces various toxic A $\beta$ species in the brain. <i>Journal of Nanobiotechnology</i> , 2023, 21, .	4.2	4
177	FDA approval of lecanemab: the real start of widespread amyloid PET use? – the EANM Neuroimaging Committee perspective. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 1553-1555.	3.3	8
178	Amyloid $\beta$ pathology in Alzheimer's disease: A nano delivery approach. <i>Vibrational Spectroscopy</i> , 2023, 126, 103510.	1.2	3
179	Neural circuit changes in neurological disorders: Evidence from in vivo two-photon imaging. <i>Ageing Research Reviews</i> , 2023, 87, 101933.	5.0	4
180	Targeting the Brain with Single-Domain Antibodies: Greater Potential Than Stated So Far?. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2632.	1.8	5
181	Technical Review of Clinical Outcomes Assessments Across the Continuum of Alzheimer's Disease. <i>Neurology and Therapy</i> , 2023, 12, 571-595.	1.4	2
182	N, F-doped graphene quantum dots effectively inhibit the fibrillization of amyloid-beta peptide (1 $\beta$ 42). <i>Materials Chemistry and Physics</i> , 2023, 299, 127522.	2.0	0
184	Effectiveness and safety of monoclonal antibodies against amyloid-beta vis-à-vis placebo in mild or moderate Alzheimer's disease. <i>Frontiers in Neurology</i> , 0, 14, .	1.1	1
185	Mast Cell Proteases Cleave Prion Proteins and a Recombinant Ig against PrP Can Activate Human Mast Cells. <i>Journal of Immunology</i> , 2023, 210, 1447-1458.	0.4	0
186	Amyloid-beta aggregation implicates multiple pathways in Alzheimer's disease: Understanding the mechanisms. <i>Frontiers in Neuroscience</i> , 0, 17, .	1.4	10
199	Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease. <i>BioDrugs</i> , 2024, 38, 5-22.	2.2	5